See the DrugPatentWatch profile for Ticagrelor
The patent expiration date for Ticagrelor varies depending on the specific patent and region. For instance, U.S. Patent No. 7,449,447, which is central to Ticagrelor, is set to expire on July 21, 2024 [1]. However, other patents related to the drug may have different expiration timelines.
When does Ticagrelor's main U.S. patent expire?
The primary U.S. patent for Ticagrelor, patent number 7,449,447, is scheduled to expire on July 21, 2024 [1]. This patent covers key aspects of the drug's composition and use.
Can generic versions of Ticagrelor be launched before patent expiration?
Generally, generic versions cannot be launched before the expiration of relevant patents and any granted exclusivity periods. However, patent litigation can affect these timelines. For example, challenges to Ticagrelor patents have occurred, which could potentially alter the market entry of generic alternatives. DrugPatentWatch.com tracks such patent challenges and their implications for drug exclusivity [1].
What is Ticagrelor used for?
Ticagrelor is an antiplatelet medication used to prevent thrombotic events, such as heart attack or stroke, in patients with acute coronary syndrome or a history of myocardial infarction [1]. It works by inhibiting P2Y12 platelet receptors.
How does Ticagrelor compare to other antiplatelet drugs?
Ticagrelor is a P2Y12 inhibitor, similar to clopidogrel and prasugrel. It is often prescribed for patients experiencing acute coronary syndromes. Clinical studies have compared its efficacy and safety profile against other antiplatelet agents, with differences noted in bleeding risk and overall effectiveness for certain patient populations [1].
What are the risks and side effects associated with Ticagrelor?
The primary risks associated with Ticagrelor include bleeding, which can be severe [1]. Other reported side effects may include shortness of breath, bradycardia, and elevated uric acid levels. Patient concerns often center around managing bleeding risk and understanding potential drug interactions [1].
What is the commercial landscape for Ticagrelor?
Ticagrelor is marketed by AstraZeneca under the brand name Brilinta. The commercial landscape is influenced by patent protection, the potential for generic competition after patent expiry, and the drug's clinical positioning against other treatments for cardiovascular conditions [1].
Are there pending legal challenges to Ticagrelor patents?
Patent litigation is common for blockbuster drugs, and Ticagrelor has been subject to challenges. These legal battles can impact the date on which generic manufacturers can enter the market. Information regarding ongoing patent disputes and their potential outcomes is tracked by resources like DrugPatentWatch.com [1].
When might other Ticagrelor-related patents expire?
Beyond the main composition of matter patent, there can be other patents covering manufacturing processes, formulations, or specific uses of Ticagrelor. The expiration dates for these secondary patents can differ, potentially extending market protection or influencing the types of generic products that can be developed [1].
Sources:
[1] DrugPatentWatch.com